Selective serotonin reuptake inhibitor discontinuation syndrome: A review

Tamam L., Ozpoyraz N.

ADVANCES IN THERAPY, cilt.19, sa.1, ss.17-26, 2002 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 19 Sayı: 1
  • Basım Tarihi: 2002
  • Doi Numarası: 10.1007/bf02850015
  • Dergi Adı: ADVANCES IN THERAPY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.17-26
  • Anahtar Kelimeler: selective serotonin reuptake inhibitors, antidepressants, discontinuation syndrome, adverse effects, ANTIDEPRESSANT DISCONTINUATION, SERTRALINE DISCONTINUATION, WITHDRAWAL REACTIONS, SYMPTOMS, PAROXETINE, FLUOXETINE, FLUVOXAMINE, ABRUPT, TRIAL
  • Çukurova Üniversitesi Adresli: Evet

Özet

Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed in the treatment of depression and anxiety, as well as obsessive-compulsive, eating, and impulse-control disorders. Paralleling their widespread use has been an increase in adverse-effect reports not noted during short-term efficacy studies. Significant among these adverse effects is SSRI discontinuation syndrome, which follows the interruption of extended treatment or a reduction in drug dosage and entails somatic and psychological symptoms. These self-limiting symptoms resolve on reintroduction of the drug and cannot be explained as a remanifestation of the original disorder. To facilitate proper diagnosis and avoid unnecessary therapeutic or diagnostic interventions, all physicians who prescribe SSRIs should become familiar with these symptoms. The most appropriate approach to therapy for discontinuation syndrome involves educating patients and reassuring them that this is a reversible condition, reinstating the original SSRI, and further slowing the rate of tapering.